High Flow Nasal Oxygenation and Gastric Insufflation in Anesthetized Patients

Ajou University School of Medicine

Status: Completed

Conditions: Gastric Distention

Treatments: Device: THRIVE

Study type: Interventional

Funder types: Other

Identifiers

NCT04629911

MED-DE1-20-424

Details and patient eligibility

About

Transnasal humidified rapid-insufflation ventilatory exchange(THRIVE), or also termed high flow nasal oxygenation (HFNO) is a method of supplying heated, humidified high concentrations of oxygen via nasal cavity.

The purpose of this study is to investigate the effect of HFNO on gastric insufflation in paralyzed anesthetized patients undergoing laryngologic surgery.

Full description

HFNO can be used during intraoperative period. HFNO reduces the risk of desaturation and prolongs the safe apnea time, compared with conventional oxygenation.

In laryngeal microsurgery, HFNO therapy make possible to perform tubeless anesthesia, providing perfect exposure of structure of the vocal cords.

HFNO have a risk for low level of positive pressure can make gastric distension, but gastric reflux or aspiration were not occurred during rapid sequence induction for emergency operation.

The purpose of this study is to investigate the effect of HFNO on gastric insufflation in paralyzed anesthetized patients undergoing laryngologic surgery.

Enrollment: 45 patients

Sex: All

Ages: 19 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• American Society of Anesthesiology physical status classification I and II
• Patients scheduled for laryngeal microsurgery under general anesthesia

Exclusion criteria

• gastroesophageal reflux
• gastric pathology
• pregnancy
• major cardiovascular, pulmonary, or cerebrovascular disease
• severe obesity (body mass index>35 kg/m2)

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

45 participants in 1 patient group

HFNO arm

Experimental group

Description:

Patients will receive HFNO therapy during laryngomicrosurgery.

Treatment:

Device: THRIVE